185 related articles for article (PubMed ID: 19807094)
21. [Pro(3)]Dyn A(1-11)-NH(2): a dynorphin analogue with high selectivity for the kappa opioid receptor.
Schlechtingen G; Zhang L; Maycock A; DeHaven RN; Daubert JD; Cassel J; Chung NN; Schiller PW; Goodman M
J Med Chem; 2000 Jul; 43(14):2698-702. PubMed ID: 10893307
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.
Fang WJ; Cui Y; Murray TF; Aldrich JV
J Med Chem; 2009 Sep; 52(18):5619-25. PubMed ID: 19715279
[TBL] [Abstract][Full Text] [Related]
23. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.
Merg F; Filliol D; Usynin I; Bazov I; Bark N; Hurd YL; Yakovleva T; Kieffer BL; Bakalkin G
J Neurochem; 2006 Apr; 97(1):292-301. PubMed ID: 16515546
[TBL] [Abstract][Full Text] [Related]
24. N-alkylated derivatives of [D-Pro10]dynorphin A-(1-11) are high affinity partial agonists at the cloned rat kappa-opioid receptor.
Soderstrom K; Choi H; Berman FW; Aldrich JV; Murray TF
Eur J Pharmacol; 1997 Nov; 338(2):191-7. PubMed ID: 9456002
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
[TBL] [Abstract][Full Text] [Related]
26. A novel acetylated analogue of dynorphin A-(1-11) amide as a kappa-opioid receptor antagonist.
Wan Q; Murray TF; Aldrich JV
J Med Chem; 1999 Aug; 42(16):3011-3. PubMed ID: 10447942
[No Abstract] [Full Text] [Related]
27. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 1. Conformational constraint in the "message" sequence.
Arttamangkul S; Murray TF; DeLander GE; Aldrich JV
J Med Chem; 1995 Jun; 38(13):2410-7. PubMed ID: 7608905
[TBL] [Abstract][Full Text] [Related]
28. Comparison with naloxone of two dynorphin A analogues with K- and delta-opioid antagonist activity.
Capasso A
Med Chem; 2009 Jan; 5(1):1-6. PubMed ID: 19149644
[TBL] [Abstract][Full Text] [Related]
29. Conformational Constraint between Aromatic Residue Side Chains in the "Message" Sequence of the Peptide Arodyn Using Ring Closing Metathesis Results in a Potent and Selective Kappa Opioid Receptor Antagonist.
Gisemba SA; Ferracane MJ; Murray TF; Aldrich JV
J Med Chem; 2021 Mar; 64(6):3153-3164. PubMed ID: 33688737
[TBL] [Abstract][Full Text] [Related]
30. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
Sirohi S; Aldrich JV; Walker BM
Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11.
Meyer JP; Collins N; Lung FD; Davis P; Zalewska T; Porreca F; Yamamura HI; Hruby VJ
J Med Chem; 1994 Nov; 37(23):3910-7. PubMed ID: 7966152
[TBL] [Abstract][Full Text] [Related]
32. Design of potent dynorphin A-(1-9) analogues devoid of supraspinal motor effects in mice.
Le HT; Michelot R; Dumont M; Shukla VK; Mayer M; Nguyen KP; Ruan H; Lemaire S
Can J Physiol Pharmacol; 1997 Jan; 75(1):9-14. PubMed ID: 9101059
[TBL] [Abstract][Full Text] [Related]
33. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
[TBL] [Abstract][Full Text] [Related]
34. Deletion of Ac-NMePhe(1) from [NMePhe(1) ]arodyn under acidic conditions, part 2: effects of substitutions on pharmacological activity.
Fang WJ; Bennett MA; Murray TF; Aldrich JV
Biopolymers; 2011; 96(1):103-10. PubMed ID: 20560148
[TBL] [Abstract][Full Text] [Related]
35. Development of highly potent and selective dynorphin A analogues as new medicines.
Lung FD; Chen CH; Liu JH
J Pept Res; 2005 Nov; 66(5):263-76. PubMed ID: 16218994
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).
Fang WJ; Murray TF; Aldrich JV
Bioorg Med Chem; 2018 Mar; 26(6):1157-1161. PubMed ID: 29273415
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of highly potent and selective cyclic dynorphin A analogues.
Kawasaki AM; Knapp RJ; Kramer TH; Wire WS; Vasquez OS; Yamamura HI; Burks TF; Hruby VJ
J Med Chem; 1990 Jul; 33(7):1874-9. PubMed ID: 1972964
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs.
Kawasaki AM; Knapp RJ; Kramer TH; Walton A; Wire WS; Hashimoto S; Yamamura HI; Porreca F; Burks TF; Hruby VJ
J Med Chem; 1993 Mar; 36(6):750-7. PubMed ID: 8096246
[TBL] [Abstract][Full Text] [Related]
39. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes.
Onali P; Dedoni S; Olianas MC
J Pharmacol Exp Ther; 2010 Jan; 332(1):255-65. PubMed ID: 19828880
[TBL] [Abstract][Full Text] [Related]
40. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Yamamoto T; Nair P; Vagner J; Largent-Milnes T; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
J Med Chem; 2008 Mar; 51(5):1369-76. PubMed ID: 18266313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
